Drug Action
Eliglustat is an inhibitor of glucosylceramide synthase.
PDF page 1146
Loading InternPractice…
Drug reference
Eliglustat is an inhibitor of glucosylceramide synthase.
PDF page 1146
Type 1 Gaucher disease (CYP2D6 poor metabolisers) (under expert supervision) ▶BY MOUTH ▶Adult: 84 mg once daily Type 1 Gaucher disease (CYP2D6 intermediate or extensive metabolisers) (under expert supervision) ▶BY MOUTH ▶Adult: 84 mg twice daily
PDF page 1146
Cardiac disease (no information available). concurrent use of Class IA and Class III antiarrhythmics. long QT syndrome (no information available)
PDF page 1146
Manufacturer advises CYP2D6 metaboliser status should be determined before initiation of treatment.
PDF page 1146
The manufacturer of Cerdelga ® has provided a Prescriber Guide, which includes a prescriber checklist.
PDF page 1146
NICE decisions ▶Eliglustat for treating type 1 Gaucher disease (June 2017) NICE HST5 Eliglustat is recommended within its marketing authorisation for treating type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers. Eliglustat is only recommended when the manufacturer provides it with the discount agreed in the patient access scheme. www.nice.org.uk/guidance/hst5 Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (December 2017) that eliglustat (Cerdelga ®) is accepted for use within NHS Scotland for the long-term treatment of adult patients with type 1 Gaucher disease who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF pages 1146, 1147
→Appendix 1: eliglustat
PDF page 1146
▶Common or very common Arthralgia. constipation. dyspepsia. fatigue. gastrointestinal disorders. nausea. palpitations ▶Frequency not known Syncope
PDF page 1146
Manufacturer advises avoid—limited information available.
PDF page 1146
Manufacturer advises avoid—present in milk in animal studies.
PDF page 1146
▶For treatment-naive patients showing less than 20% spleen volume reduction after 9 months of treatment, manufacturer advises monitor for further improvement or consider an alternative treatment. ▶For patients with stable disease who have switched from enzyme replacement therapy, manufacturer advises monitor for disease progression—consider reinstitution of enzyme replacement therapy or an alternative treatment if response sub-optimal.
PDF page 1146
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 10 ▶Cerdelga (Sanofi) A Eliglustat (as Eliglustat tartrate) 84.4 mg Cerdelga 84mg capsules | 56 capsule P £19,164.96 ENZYMES
PDF page 1147
A patient alert card should be provided.
PDF page 1146
84 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1146
84 mg twice daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1146